MIRA Pharmaceuticals Investor Presentation 2024

MIRA Pharmaceuticals is developing early-stage pre-clinical product candidates including MIRA1a and KETAMIR for neuropsychiatric indications. The company is led by experienced biotech executives and scientific advisors from Johns Hopkins and IQVIA with expertise in ketamine research and clinical development.